TechCrunchby Marina Temkin
Original published: Updated on DevPick:

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
AI summary
Editorial policyUpdated on DevPick:

AI biotech company Enveda secured $311 million in funding, reaching a valuation of $2 billion.

Key points

  • •This funding round set Enveda's valuation at $2 billion.
  • •The company is currently testing drugs for skin diseases and weight loss maintenance after stopping GLP-1 medication.
  • •The raised funds will be used to advance natural-derived AI drug discovery to the clinical trial stage.
#AI Companies & Funding#LLM / Model Trends
See more